Atherosclerosis
Volume 183, Issue 1 , Pages 49-55 , November 2005

Aspirin inhibits thrombin action on endothelial cells via up-regulation of aminopeptidase N/CD13 expression

Received 5 October 2004 ,Revised 3 March 2005 ,Accepted 8 March 2005.

References 

  1. Juul-Moller S, Edvardsson N, Jahnmatz B, et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris, The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet. 1992;340:1421–1425
  2. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81–106
  3. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994;265:956–959
  4. Grilli M, Pizzi M, Memo M, Spano P. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappa B activation. Science. 1996;274:1383–1385
  5. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature. 1998;396:77–80
  6. Dong Z, Huang C, Brown RE, Ma WY. Inhibition of activator protein 1 activity and neoplastic transformation by aspirin. J Biol Chem. 1997;272:9962–9970
  7. Huang C, Ma WY, Hanenberger D, et al. Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice. J Biol Chem. 1997;272:26325–26331
  8. Oberle S, Polte T, Abate A, Podhaisky HP, Schroder H. Aspirin increases ferritin synthesis in endothelial cells: a novel antioxidant pathway. Circ Res. 1998;82:1016–1020
  9. Jurivich DA, Sistonen L, Kroes RA, Morimoto RI. Effect of sodium salicylate on the human heat shock response. Science. 1992;255:1243–1245
  10. Kagawa A, Azuma H, Akaike M, Kanagawa Y, Matsumoto T. Aspirin reduces apolipoprotein(a) (apo(a)) production in human hepatocytes by suppression of apo(a) gene transcription. J Biol Chem. 1999;274:34111–34115
  11. Riemann D, Kehlen A, Langner J. CD13—not just a marker in leukemia typing. Immunol Today. 1999;20:83–88
  12. Coller BS, Ward P, Ceruso M, et al. Thrombin receptor activating peptides: importance of the N-terminal serine and its ionization state as judged by pH dependence, nuclear magnetic resonance spectroscopy, and cleavage by aminopeptidase M. Biochemistry. 1992;31:11713–11720
  13. Ross R. The pathogenesis of atherosclerosis—an update. N Engl J Med. 1986;314:488–500
  14. Fingerle J, Johnson R, Clowes AW, Majesky MW, Reidy MA. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. Proc Natl Acad Sci USA. 1989;86:8412–8416
  15. Nelken NA, Soifer SJ, O’Keefe J, et al. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest. 1992;90:1614–1621
  16. Waugh JM, Li-Hawkins J, Yuksel E, et al. Thrombomodulin overexpression to limit neointima formation. Circulation. 2000;102:332–337
  17. Iuchi T, Akaike M, Mitsui T, et al. Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circ Res. 2003;92:81–87
  18. Aihara K, Azuma H, Akaike M, et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem. 2004;279:35798–35802
  19. Look AT, Ashmun RA, Shapiro LH, Peiper SC. Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J Clin Invest. 1989;83:1299–1307
  20. Shapiro LH, Ashmun RA, Roberts WM, Look AT. Separate promoters control transcription of the human aminopeptidase N gene in myeloid and intestinal epithelial cells. J Biol Chem. 1991;266:11999–12007
  21. Fujii H, Nakajima M, Saiki I, et al. Human melanoma invasion and metastasis enhancement by high expression of aminopeptidase N/CD13. Clin Exp Metastasis. 1995;13:337–344
  22. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–275
  23. Shipp MA, Look AT. Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key. Blood. 1993;82:1052–1070
  24. Bhagwat SV, Lahdenranta J, Giordano R, et al. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood. 2001;97:652–659
  25. Bhagwat SV, Petrovic N, Okamoto Y, Shapiro LH. The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis. Blood. 2003;101:1818–1826
  26. Undas A, Undas R, Musial J, Szczeklik A. A low dose of aspirin (75mg/day) lowers thrombin generation to a similar extent as a high dose of aspirin (300mg/day). Blood Coagul Fibrinolysis. 2000;11:231–234
  27. Musial J, Undas A, Undas R, Brozek J, Szczeklik A. Treatment with simvastatin and low-dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline-high cholesterol levels. Thromb Haemost. 2001;85:221–225
  28. Undas A, Brummel K, Musial J, Mann KG, Szczeklik A. Blood coagulation at the site of microvascular injury: effects of low-dose aspirin. Blood. 2001;98:2423–2431
  29. Weber C, Erl W, Pietsch A, Weber PC. Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation. 1995;91:1914–1917
  30. Vervoordeldonk MJ, Pineda Torra IM, Aarsman AJ, van den Bosch H. Aspirin inhibits expression of the interleukin-1beta-inducible group II phospholipase A2. FEBS Lett. 1996;397:108–112
  31. Oeth P, Mackman N. Salicylates inhibit lipopolysaccharide-induced transcriptional activation of the tissue factor gene in human monocytic cells. Blood. 1995;86:4144–4152
  32. Muller DN, Heissmeyer V, Dechend R, et al. Aspirin inhibits NF-kappaB and protects from angiotensin II-induced organ damage. FASEB J. 2001;15:1822–1824
  33. Kim JK, Kim YJ, Fillmore JJ, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest. 2001;108:437–446
  34. Gao Z, Zuberi A, Quon MJ, Dong Z, Ye J. Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases. J Biol Chem. 2003;278:24944–24950
  35. Petrovic N, Bhagwat SV, Ratzan WJ, Ostrowski MC, Shapiro LH. CD13/APN transcription is induced by RAS/MAPK-mediated phosphorylation of Ets-2 in activated endothelial cells. J Biol Chem. 2003;278:49358–49368
  36. Coller BS, Springer KT, Scudder LE, et al. Substituting isoserine for serine in the thrombin receptor activation peptide SFLLRN confers resistance to aminopeptidase M-induced cleavage and inactivation. J Biol Chem. 1993;268:20741–20743
  37. Coughlin SR. Protease-activated receptors in vascular biology. Thromb Haemost. 2001;86:298–307

PII: S0021-9150(05)00190-5

doi: 10.1016/j.atherosclerosis.2005.03.003

Atherosclerosis
Volume 183, Issue 1 , Pages 49-55 , November 2005

Article Tools

* Image Usage & Resolution